<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02351167</url>
  </required_header>
  <id_info>
    <org_study_id>201305128</org_study_id>
    <secondary_id>1R01DA038076-01A1</secondary_id>
    <nct_id>NCT02351167</nct_id>
  </id_info>
  <brief_title>Genetically Informed Smoking Cessation Trial</brief_title>
  <acronym>GISC</acronym>
  <official_title>Genetically Informed Smoking Cessation Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' goal is to identify the most appropriate smoking cessation treatments for
      smokers based on genetic information. Smokers try to quit smoking but relapses are common.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' goal is to determine whether genetic markers can be used to optimize
      smoking cessation pharmacotherapy to enhance efficacy, medication adherence, and reduce side
      effects. Smoking is a leading cause of preventable death and disability, and smoking
      cessation reverses the risk of mortality. However, cessation failure is common despite
      available cessation medications, which are associated with different efficacy, side effects,
      adherence, use constraints, and costs. This challenge can be addressed by improving current
      treatments via personalized medicine based on individual genetic markers to maximize efficacy
      and minimize side effects.

      The investigators propose a prospective, genotype-based stratified randomization trial to
      compare two smoking cessation medications (combination NRT [patch and lozenge], varenicline
      vs. placebo) for 3 months in 720 smokers with known genotypes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2015</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>7-day Point Prevalence Quit Rate</measure>
    <time_frame>Week 12</time_frame>
    <description>The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous Abstinence</measure>
    <time_frame>12 weeks (with first 1 week initial grace period)</time_frame>
    <description>The definition of this measure requires: Not taking even 1 cigarette puff from target quit date to end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day Point Prevalence Quit Rate</measure>
    <time_frame>Week 24</time_frame>
    <description>The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days to Lapse and Relapse</measure>
    <time_frame>Assessed from the target quit day through 52 weeks</time_frame>
    <description>The number of days to lapse is defined as the number of days from the target quit date until the participant reports smoking (even a single puff). The number of days to relapse is defined as the number of days from the target quit day until the first of seven consecutive days of smoking.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial Cessation</measure>
    <time_frame>Assessed for the first seven days after the target quit date</time_frame>
    <description>Defined as at least 1 day of abstinence during the first 7 days after the target quit day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Models of Abstinence Outcomes Across Multiple Time Points</measure>
    <time_frame>0-52 Weeks</time_frame>
    <description>The definition of this measure requires; no self-reported smoking (not even a puff of a cigarette) for at least 7 days prior to the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longitudinal Models of Smoking Quantity in Cigarettes Per Day Outcomes Across Multiple Time Points.</measure>
    <time_frame>0-52 Weeks</time_frame>
    <description>The definition of this measure requires self-reported cigarettes per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence</measure>
    <time_frame>Pre-quit week to Week 12</time_frame>
    <description>Adherence is the proportion of expected medication (varenicline, patch, lozenge) taken as advised during pre-quit week to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects</measure>
    <time_frame>Pre-quit week to Week 12</time_frame>
    <description>All reported side effects (occurring&gt;4%) will be summarized and presented for the study. In addition, the investigators will further identify a pre-specified set of key side effects as being related to drug agonist effects (e.g., nausea, vomiting, racing heart, headache, and sleep disturbance). These will be analyzed as rate of occurrence during the period of medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal</measure>
    <time_frame>Pre-quit, quit, week 1, week 2, and week 4</time_frame>
    <description>Withdrawal severity is assessed by Wisconsin Smoking Withdrawal Scale (WSWS), there are 28 items.
Participants rate each item on a scale of 0-4 (0=Strongly disagree, 1=Disagree, 2=Feel neutral, 3=Agree, 4=Strongly agree). The subscale to each item is determined on how high they agree on the scale. For some items, the subscale is determined on how low they agreed. Each score is determined by the mean of each item that applies. Higher means indicate greater withdrawal.
The scores were calculated by averaging a mean score of each item for each participant with data from time point pre-quit, quit, week 1, week 2, and week 4. The mean score for each participant was averaged for each item and a mean score was taken for each treatment condition (cNRT, Varenicline, Placebo). These data are reported as mean withdrawal scores and not change in withdrawal scores.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">822</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Combination NRT and Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Varenicline (Chantix) and Counseling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Medicine and Counseling</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination NRT (Nicotine patch, Nicotine lozenge)</intervention_name>
    <arm_group_label>Combination NRT and Counseling</arm_group_label>
    <other_name>Nicoderm CQ</other_name>
    <other_name>Nicotine Polacrilex Lozenge</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <arm_group_label>Varenicline (Chantix) and Counseling</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Medicine and Counseling</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intensive smoking counseling</intervention_name>
    <arm_group_label>Combination NRT and Counseling</arm_group_label>
    <arm_group_label>Placebo Medicine and Counseling</arm_group_label>
    <arm_group_label>Varenicline (Chantix) and Counseling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult (≥21 years of age), seeking treatment for smoking cessation.

          2. Able to speak English,

          3. Active smoking (Cigarettes Per Day (CPD) ≥5), and exhaled Carbon Monoxide (CO) ≥8 ppm

          4. Agree to participate in this randomized smoking cessation trial with follow up
             assessments up to 12 months.

        Exclusion Criteria:

          1. Pregnancy or breast feeding,

          2. Active use or recent use (&lt; or equal to 1 month) of medication or e-cigarettes for
             nicotine dependence/smoking cessation, or use of e-cigarettes for more than 9 days in
             the prior month,

          3. Allergy to nicotine patch, lozenge, or varenicline,

          4. Unwillingness to prevent pregnancy during the medication phase and 1 month afterwards
             (women only),

          5. Significant cardiac conditions (myocardial infarction, unstable angina, coronary
             angioplasty, cardiac bypass) or serious arrhythmia in past 6 months,

          6. Current heavy alcohol consumption (≥6 drinks/day, 6 days/week),

          7. Active psychosis or poorly controlled depression within the past 6 months,

          8. Any prior suicide attempt or suicidal ideation within the past 6 months,

          9. End stage renal disease with hemodialysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Shiun Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 26, 2015</study_first_submitted>
  <study_first_submitted_qc>January 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <results_first_submitted>December 20, 2019</results_first_submitted>
  <results_first_submitted_qc>March 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2020</results_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Counseling</keyword>
  <keyword>Genetics and Genomics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02351167/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02351167/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to participant enrollment on 05/20/2015 and closed to participant enrollment on 07/23/2018.</recruitment_details>
      <pre_assignment_details>-The study consented 894 participants and 72 were excluded after consenting due to no longer wanting to participate or not meeting all the eligibility criteria prior to randomization. The 72 were not considered enrolled in the study per the policy of the institution.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination NRT and Counseling</title>
          <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="P2">
          <title>Varenicline (Chantix) and Counseling</title>
          <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="P3">
          <title>Placebo Medicine and Counseling</title>
          <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="274"/>
                <participants group_id="P3" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="256"/>
                <participants group_id="P3" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Combination NRT and Counseling</title>
          <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="B2">
          <title>Varenicline (Chantix) and Counseling</title>
          <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="B3">
          <title>Placebo Medicine and Counseling</title>
          <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="273"/>
            <count group_id="B4" value="822"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="261"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="258"/>
                    <measurement group_id="B4" value="781"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.3" spread="11.2"/>
                    <measurement group_id="B2" value="46.6" spread="11.0"/>
                    <measurement group_id="B3" value="46.6" spread="11.5"/>
                    <measurement group_id="B4" value="46.5" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="161"/>
                    <measurement group_id="B4" value="449"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="271"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="268"/>
                    <measurement group_id="B4" value="804"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="270"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="516"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="273"/>
                    <measurement group_id="B4" value="822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>7-day Point Prevalence Quit Rate</title>
        <description>The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Quit Rate</title>
          <description>The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Abstinence</title>
        <description>The definition of this measure requires: Not taking even 1 cigarette puff from target quit date to end of treatment.</description>
        <time_frame>12 weeks (with first 1 week initial grace period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Abstinence</title>
          <description>The definition of this measure requires: Not taking even 1 cigarette puff from target quit date to end of treatment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>7-day Point Prevalence Quit Rate</title>
        <description>The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>7-day Point Prevalence Quit Rate</title>
          <description>The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days to Lapse and Relapse</title>
        <description>The number of days to lapse is defined as the number of days from the target quit date until the participant reports smoking (even a single puff). The number of days to relapse is defined as the number of days from the target quit day until the first of seven consecutive days of smoking.</description>
        <time_frame>Assessed from the target quit day through 52 weeks</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Cessation</title>
        <description>Defined as at least 1 day of abstinence during the first 7 days after the target quit day.</description>
        <time_frame>Assessed for the first seven days after the target quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Cessation</title>
          <description>Defined as at least 1 day of abstinence during the first 7 days after the target quit day.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217"/>
                    <measurement group_id="O2" value="186"/>
                    <measurement group_id="O3" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Models of Abstinence Outcomes Across Multiple Time Points</title>
        <description>The definition of this measure requires; no self-reported smoking (not even a puff of a cigarette) for at least 7 days prior to the assessment.</description>
        <time_frame>0-52 Weeks</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longitudinal Models of Smoking Quantity in Cigarettes Per Day Outcomes Across Multiple Time Points.</title>
        <description>The definition of this measure requires self-reported cigarettes per day.</description>
        <time_frame>0-52 Weeks</time_frame>
        <posting_date>08/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence</title>
        <description>Adherence is the proportion of expected medication (varenicline, patch, lozenge) taken as advised during pre-quit week to week 12</description>
        <time_frame>Pre-quit week to Week 12</time_frame>
        <population>Not all participants were evaluable for this outcome measure due to data not being available. Also the Varenicline (Chantix) and Counseling Arm did not receive the lozenge or the patch. The Combination NRT and Counseling Arm did not receive Varenicline (Chantix)</population>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence</title>
          <description>Adherence is the proportion of expected medication (varenicline, patch, lozenge) taken as advised during pre-quit week to week 12</description>
          <population>Not all participants were evaluable for this outcome measure due to data not being available. Also the Varenicline (Chantix) and Counseling Arm did not receive the lozenge or the patch. The Combination NRT and Counseling Arm did not receive Varenicline (Chantix)</population>
          <units>proportion of expected medication taken</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="234"/>
                <count group_id="O2" value="242"/>
                <count group_id="O3" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patch</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.34"/>
                    <measurement group_id="O3" value="0.57" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lozenge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="234"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.39"/>
                    <measurement group_id="O3" value="0.57" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varenicline (Chantix)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="242"/>
                    <count group_id="O3" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.67" spread="0.32"/>
                    <measurement group_id="O3" value="0.70" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects</title>
        <description>All reported side effects (occurring&gt;4%) will be summarized and presented for the study. In addition, the investigators will further identify a pre-specified set of key side effects as being related to drug agonist effects (e.g., nausea, vomiting, racing heart, headache, and sleep disturbance). These will be analyzed as rate of occurrence during the period of medication use.</description>
        <time_frame>Pre-quit week to Week 12</time_frame>
        <population>Not all participants were evaluable for this outcome measure due to data not being available.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects</title>
          <description>All reported side effects (occurring&gt;4%) will be summarized and presented for the study. In addition, the investigators will further identify a pre-specified set of key side effects as being related to drug agonist effects (e.g., nausea, vomiting, racing heart, headache, and sleep disturbance). These will be analyzed as rate of occurrence during the period of medication use.</description>
          <population>Not all participants were evaluable for this outcome measure due to data not being available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="241"/>
                <count group_id="O3" value="208"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Racing Heart</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep Disturbance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Withdrawal</title>
        <description>Withdrawal severity is assessed by Wisconsin Smoking Withdrawal Scale (WSWS), there are 28 items.
Participants rate each item on a scale of 0-4 (0=Strongly disagree, 1=Disagree, 2=Feel neutral, 3=Agree, 4=Strongly agree). The subscale to each item is determined on how high they agree on the scale. For some items, the subscale is determined on how low they agreed. Each score is determined by the mean of each item that applies. Higher means indicate greater withdrawal.
The scores were calculated by averaging a mean score of each item for each participant with data from time point pre-quit, quit, week 1, week 2, and week 4. The mean score for each participant was averaged for each item and a mean score was taken for each treatment condition (cNRT, Varenicline, Placebo). These data are reported as mean withdrawal scores and not change in withdrawal scores.</description>
        <time_frame>Pre-quit, quit, week 1, week 2, and week 4</time_frame>
        <population>Not all participants were evaluable for this outcome measure due to data not being available.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination NRT and Counseling</title>
            <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O2">
            <title>Varenicline (Chantix) and Counseling</title>
            <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
          </group>
          <group group_id="O3">
            <title>Placebo Medicine and Counseling</title>
            <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Withdrawal</title>
          <description>Withdrawal severity is assessed by Wisconsin Smoking Withdrawal Scale (WSWS), there are 28 items.
Participants rate each item on a scale of 0-4 (0=Strongly disagree, 1=Disagree, 2=Feel neutral, 3=Agree, 4=Strongly agree). The subscale to each item is determined on how high they agree on the scale. For some items, the subscale is determined on how low they agreed. Each score is determined by the mean of each item that applies. Higher means indicate greater withdrawal.
The scores were calculated by averaging a mean score of each item for each participant with data from time point pre-quit, quit, week 1, week 2, and week 4. The mean score for each participant was averaged for each item and a mean score was taken for each treatment condition (cNRT, Varenicline, Placebo). These data are reported as mean withdrawal scores and not change in withdrawal scores.</description>
          <population>Not all participants were evaluable for this outcome measure due to data not being available.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="261"/>
                <count group_id="O2" value="263"/>
                <count group_id="O3" value="253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="0.75"/>
                    <measurement group_id="O2" value="1.49" spread="0.81"/>
                    <measurement group_id="O3" value="1.47" spread=".79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.79"/>
                    <measurement group_id="O2" value="1.81" spread="0.90"/>
                    <measurement group_id="O3" value="1.82" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="0.64"/>
                    <measurement group_id="O2" value="1.48" spread="0.76"/>
                    <measurement group_id="O3" value="1.42" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="0.85"/>
                    <measurement group_id="O2" value="2.20" spread="0.86"/>
                    <measurement group_id="O3" value="2.50" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hunger</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.84"/>
                    <measurement group_id="O2" value="2.28" spread="0.80"/>
                    <measurement group_id="O3" value="2.17" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sadness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.63"/>
                    <measurement group_id="O2" value="1.11" spread="0.69"/>
                    <measurement group_id="O3" value="1.11" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.82"/>
                    <measurement group_id="O2" value="1.70" spread="0.89"/>
                    <measurement group_id="O3" value="1.54" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected until from enrollment until 1 year post target quit date. Post-study adverse events will be recorded when the subject volunteers to report such events to the investigator team.</time_frame>
      <desc>Adverse events are assessed in each follow-up visit to the end of the trial. With respect to the pharmacotherapy, participants will be made aware of the common side effects before they consent to participate in the study. During each study visit, participants are asked about common side effects associated with the drug(s) as well as any other symptoms participants report regardless of attribution to the drug(s).</desc>
      <group_list>
        <group group_id="E1">
          <title>Combination NRT and Counseling</title>
          <description>Combination Nicotine replacement therapy (cNRT) (patch and lozenge) and smoking cessation counseling will be provided to participants. Lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="E2">
          <title>Varenicline (Chantix) and Counseling</title>
          <description>Varenicline (pill) and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Seven smoking cessation counseling sessions will be given during treatment.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Medicine and Counseling</title>
          <description>Placebo pill and smoking cessation counseling will be provided to participants for 12 weeks with 1 week pre-quit titration. Placebo lozenges will be given for 12 weeks with a 1 week pre-quit titration and patch for 12 weeks. Seven smoking counseling sessions will be given during treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Death due to cardiorespiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Death due to congestive heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Left bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Diverticulosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hemorrhoid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death, unknown</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Death due to natural causes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Ammonia poisoning of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Antibiotic spacer for MRSA infection in knee</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cellulitis, right hand</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Surgical incision site infection (post-surgery)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Infection of second toe on left foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>MRSA infection in knee</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Severe sinus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Severe tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Broken arm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Broken collarbone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Broken ribs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Cervical disc fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Complication from gastric bypass surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Death due to heroin overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Gunshot wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Homicide by gunshot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Motor vehicle accident (injury of intervertebral discs T10-12)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Partial amputation of leg due to MRSA infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Struck by vehicle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Sternum fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Inter-vertebral dis herniation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death due to Lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Death due to brain tumor complications</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Lung cancer (stage 4)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Bell's palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bipolar depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Unspecified mood disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to kidney failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Kidney stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Stage 4 endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chronic sinus necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Trouble breathing due to COPD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abdominal hysterectomy due to endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Foot surgery to fix broken toes on right foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hip replacement surgery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hysterectomy due to cervical cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hysterectomy due to enlarged fallopian tubes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Knee surgery for osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Left knee replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Minor procedure to clean wound on right foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Surgery for aortic valve stenosis and cardiac bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Urethral sling surgery due to urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="193" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="175" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid, slow, pounding, or irregular heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Chest tightness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Mouth problems (e.g. pain or sore)</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling in face or hands</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Swelling or tingling in mouth or throat</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Feeling worried, nervous, scared, or anxious</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Feeling panicky or having panic attacks</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Feeling agitated and restless</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Feeling hostile or angry towards others</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Feeling significantly down, depressed, or hopeless</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Trouble breathing</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Itching/hives</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="273"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="274"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="273"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Li-Shiun Chen, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-3932</phone>
      <email>li-shiun@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

